SecBot SecBot
6-K ·Filed May 12, 2026

IMTX

Immatics N.V.
BEARISH
Impact 6/10
Horizonmonths Processed6mo ago SEC0001193125-26-218152
Notable filing: 6-K
Actionable Insight ▼ Bearish

The widening operating loss and revenue decline are negative signals for a pre-revenue biotech, but the cash runway into 2028 and upcoming SUPRAME data catalysts provide a binary event framework. Traders should watch for SUPRAME interim analysis triggers in 2026 as the primary catalyst, positive data could reverse sentiment, while delays or negative readouts would pressure the stock significantly given the elevated burn rate.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.39
T+0 close · May 12, 2026 · via day close
Latest settled
−17.30%
T+60 · $9.42
Vs SPY
−21.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $11.39entry
  2. T+1 · 6mo ago −5.27%α −5.84% · $10.79
  3. T+5 · 6mo ago −6.76%α −6.84% · $10.62
  4. T+20 · 5mo ago −22.12%α −20.40% · $8.87
  5. T+60 · 3mo ago −17.30%α −21.68% · $9.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immatics reported Q1 2026 financial results showing a net loss of €57.8 million ($66.5 million) on revenue of €7.6 million ($8.7 million), compared to a net loss of €39.9 million on revenue of €18.6 million in Q1 2025. Revenue declined 59% YoY due to lower cost recognition on collaboration agreements, while R&D expenses surged 41% to €59.2 million driven by the SUPRAME Phase 3 trial. Cash and equivalents plus other financial assets stood at €453.6 million ($521.5 million), with cash runway projected into 2028. The company reiterated key 2026 catalysts including SUPRAME interim/final analysis triggers and multiple ASCO data presentations, but the widening operating loss and revenue decline overshadow pipeline progress.

Key Facts

  • Net loss widened to €57.8 million in Q1 2026 from €39.9 million in Q1 2025, a 45% increase
  • Revenue from collaboration agreements fell 59% to €7.6 million from €18.6 million YoY
  • R&D expenses increased 41% to €59.2 million, primarily from SUPRAME Phase 3 trial costs
  • Operating loss deepened to €66.1 million from €35.4 million YoY
  • Cash and equivalents plus other financial assets: €453.6 million ($521.5 million) as of March 31, 2026
  • Cash runway projected into 2028; ATM offering raised €21.2 million net in March 2026
  • Accumulated deficit reached €843.8 million as of March 31, 2026
  • SUPRAME Phase 3 interim and final analyses expected to be triggered in 2026; BLA submission targeted for H1 2027
  • Multiple clinical data readouts expected at 2026 ASCO meeting across cell therapy and bispecific programs
  • Moderna collaboration achieved IND submission milestone triggering a milestone payment to Immatics

Financial Impact

Revenue declined €11.0 million YoY (59% decrease); operating loss increased €30.7 million (87% increase); net loss increased €18.0 million (45% increase)

revenuenet lossoperating lossR&D expensescash burn

Risk Factors

  • Revenue decline of 59% YoY with no product sales and collaboration revenue dependent on cost recognition timing
  • Operating cash burn of €42.0 million in Q1 2026, up 23% from €34.2 million in Q1 2025
  • Clinical trial risk: SUPRAME Phase 3 interim/final analysis outcomes are binary and unpredictable
  • No approved products; entirely dependent on clinical trial success and regulatory approvals
  • Dilution risk: $150 million ATM program remains available for future capital raises

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-218152
Document: imtx-ex99_2.htm0001193125-26-218152
Document: immatics_n.v._6-k_q126.htm0001193125-26-218152
Document: 0001193125-26-218152-index-headers.html0001193125-26-218152
Document: 0001193125-26-218152-index.html0001193125-26-218152
Document: 0001193125-26-218152.txt0001193125-26-218152

Track record

23 reports on IMTX

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +11.00% at T+20 after the Aug 26, 2026 report. 8 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
  3. Nov 10, 20266d ago 6-K Neutral 5/10 No price data
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
  5. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  6. Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  7. Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
  8. Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
  9. Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
  10. Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026